PL2248517T3 - Stężone formulacje farmaceutyczne stabilizujące komórki tuczne - Google Patents

Stężone formulacje farmaceutyczne stabilizujące komórki tuczne

Info

Publication number
PL2248517T3
PL2248517T3 PL09006294T PL09006294T PL2248517T3 PL 2248517 T3 PL2248517 T3 PL 2248517T3 PL 09006294 T PL09006294 T PL 09006294T PL 09006294 T PL09006294 T PL 09006294T PL 2248517 T3 PL2248517 T3 PL 2248517T3
Authority
PL
Poland
Prior art keywords
concentrated
pharmaceutical formulations
mast cell
cell stabilizing
stabilizing pharmaceutical
Prior art date
Application number
PL09006294T
Other languages
English (en)
Inventor
Manfred Keller
Roman Egle
Original Assignee
Pari Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pari Pharma Gmbh filed Critical Pari Pharma Gmbh
Publication of PL2248517T3 publication Critical patent/PL2248517T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL09006294T 2009-05-08 2009-05-08 Stężone formulacje farmaceutyczne stabilizujące komórki tuczne PL2248517T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09006294.4A EP2248517B1 (en) 2009-05-08 2009-05-08 Concentrated mast cell stabilizing pharmaceutical formulations

Publications (1)

Publication Number Publication Date
PL2248517T3 true PL2248517T3 (pl) 2014-08-29

Family

ID=40934943

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09006294T PL2248517T3 (pl) 2009-05-08 2009-05-08 Stężone formulacje farmaceutyczne stabilizujące komórki tuczne

Country Status (6)

Country Link
US (1) US9198859B2 (pl)
EP (1) EP2248517B1 (pl)
JP (1) JP5863641B2 (pl)
ES (1) ES2457442T3 (pl)
PL (1) PL2248517T3 (pl)
WO (1) WO2010128111A1 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3067047B1 (en) 2005-12-08 2022-04-20 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
PL2852391T3 (pl) 2012-05-21 2022-04-11 Insmed Incorporated Układy do leczenia infekcji płuc
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
EP3563849A3 (en) 2012-10-25 2020-02-12 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US10124066B2 (en) 2012-11-29 2018-11-13 Insmed Incorporated Stabilized vancomycin formulations
WO2015002703A1 (en) * 2013-05-23 2015-01-08 Aztherapies, Inc Methods for delivering cromolyn
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
CN110305095A (zh) 2013-10-22 2019-10-08 综合医院公司 色甘酸衍生物以及成像和治疗的相关方法
ES2792682T3 (es) * 2014-02-10 2020-11-11 Respivant Sciences Gmbh Métodos para el tratamiento de enfermedades pulmonares con estabilizadores de mastocitos
PL3104853T3 (pl) * 2014-02-10 2020-05-18 Respivant Sciences Gmbh Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych
LT3466432T (lt) 2014-05-15 2020-12-28 Insmed Incorporated Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
WO2018044942A1 (en) 2016-08-31 2018-03-08 Patara Pharma, LLC Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
JP2019524865A (ja) 2016-08-31 2019-09-05 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ/ミクログリア
EP3522983A4 (en) * 2016-10-07 2020-06-03 Respivant Sciences GmbH CROMOLYN COMPOSITION FOR TREATING LUNG FIBROSIS
KR101861163B1 (ko) * 2017-04-26 2018-05-25 삼천당제약주식회사 안과용 약학 조성물
JP7202376B2 (ja) 2017-07-20 2023-01-11 エーゼットセラピーズ, インコーポレイテッド クロモリンナトリウムおよびイブプロフェンの粉末製剤
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
JP7449275B2 (ja) 2018-05-02 2024-03-13 インスメッド インコーポレイテッド リポソーム薬物製剤の製造方法
AU2019299347A1 (en) 2018-07-02 2021-01-21 Aztherapies, Inc. Powdered formulations of cromolyn sodium and alpha-lactose
MX2021006869A (es) 2018-12-10 2021-07-02 Massachusetts Gen Hospital Esteres de cromolin y usos de los mismos.
CN110960514A (zh) * 2019-12-23 2020-04-07 杭州百诚医药科技股份有限公司 一种吸入用复方多索茶碱溶液及其制备方法
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
WO2022146914A1 (en) 2020-12-28 2022-07-07 The General Hospital Corporation Cromolyn derivatives and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2167300B (en) * 1984-11-23 1988-11-23 Fisons Plc Formulations
GB8520133D0 (en) 1985-08-10 1985-09-18 Fisons Plc Mixtures
DE3700379A1 (de) 1987-01-08 1988-07-21 Mann Gerhard Chem Pharm Fab Konservierte augentropfen mit einem gehalt an cromoglicinsaeure
EP0413583A3 (en) 1989-08-18 1991-07-17 Dey Laboratories; Inc. Clear, stable cromolyn formulation
GB9214390D0 (en) * 1992-07-07 1992-08-19 Fisons Plc Formulations
DE19539532C2 (de) 1995-10-24 1999-02-25 Mann Gerhard Chem Pharm Fab Ophthalmisches Cromoglicat-Gelpräparat
US6004949A (en) 1995-12-27 1999-12-21 Showa Yakuhin Kako Co., Ltd. Aqueous composition containing cromoglycic acid
US20040045546A1 (en) * 2002-09-05 2004-03-11 Peirce Management, Llc Pharmaceutical delivery system for oral inhalation through nebulization consisting of inert substrate impregnated with substance (S) to be solubilized or suspended prior to use
DE102005038619A1 (de) 2005-08-16 2007-02-22 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung mit einer Ampulle für die Bevorratung eines zu vernebelnden Medikaments
US8263645B2 (en) 2006-02-03 2012-09-11 Pari Pharma Gmbh Disodium cromoglycate compositions and methods for administering same
MX2008010222A (es) * 2006-02-10 2008-10-17 Pari Pharma Gmbh Antibioticos nebulizados para terapia de inhalacion.
EP2030644A1 (en) 2007-08-31 2009-03-04 PARI Pharma GmbH Aerosols for sinunasal drug delivery
DE102007056462B4 (de) 2007-11-23 2011-10-27 Pari Pharma Gmbh Einwegampulle für eine Vorrichtung zur Erzeugung von Aerosolen

Also Published As

Publication number Publication date
WO2010128111A1 (en) 2010-11-11
US20120118991A1 (en) 2012-05-17
JP2012526084A (ja) 2012-10-25
JP5863641B2 (ja) 2016-02-16
ES2457442T3 (es) 2014-04-25
US9198859B2 (en) 2015-12-01
EP2248517A1 (en) 2010-11-10
EP2248517B1 (en) 2014-03-26

Similar Documents

Publication Publication Date Title
PL2248517T3 (pl) Stężone formulacje farmaceutyczne stabilizujące komórki tuczne
HUS2000009I1 (hu) Kétrétegû tabletta készítmények
SMT202300282T1 (it) Formulazioni farmaceutiche altamente concentrate
IL225415A0 (en) Electrolytic formulations
ZA201106050B (en) Dye-polymers formulations
BRPI1016228A2 (pt) formulações de eletrólito compatibilizadas
ZA201200719B (en) Pharmaceutical formulation
EP2512490A4 (en) S-ADENOSYLMETHIONINE FORMULATIONS WITH INCREASED BIOAVAILABILITY
IL219264A0 (en) Docetaxel formulations with lipoic acid
IL269369A (en) The vehicles are improved
GB0919210D0 (en) Formulations
GB0909134D0 (en) Cathode
IL217887A0 (en) Concentrated polypeptide formulations with reduced viscosity
AP2013006687A0 (en) Formulations
PT2568970T (pt) Formulações farmacêuticas estáveis contendo um anti-histamínico
EP2473168A4 (en) PHARMACEUTICAL FORMULATIONS FOR INDIBULIN
IL217390A0 (en) Formulations
PL2261444T3 (pl) Maszt
AP2013006689A0 (en) Formulations
HU0900086V0 (en) Mast
GB0917744D0 (en) Formulations
GB201012047D0 (en) Pharmaceutical formulations
GB201012046D0 (en) Pharmaceutical formulations
GB0914489D0 (en) Improved formulations
AU2009905633A0 (en) Formulations